Type 2 cytokine receptor and nucleic acids encoding same
AssigneeWyeth
InventorsLynette Fouser, Wei Liu, Bijia Deng
Life of this patent
Estimating the term…
Abstract
The present invention provides novel isolated CRF2-12 polynucleotides and polypeptides encoded by the CRF2-12 polynucleotides. Also provided are the antibodies that immunospecifically bind to a CRF2-12 polypeptide or any derivative (including fusion derivative), variant, mutant or fragment of the CRF2-12 polypeptide, polynucleotide or antibody. The invention additionally provides methods in which the CRF2-12 polypeptide, polynucleotide and antibody are utilized in the detection and treatment of a broad range of pathological states, as well as to other uses.
Claims64
An isolated nucleic acid molecule encoding a polypeptide comprising amino acids 21-66 of SEQ ID NO:2, or the complement of said nucleic acid molecule.
An isolated nucleic acid molecule encoding a polypeptide comprising amino acids 21-66 of SEQ ID NO:2, or one or more substitutions relative to the amino acid sequence of SEQ ID NO:2, or the complement of said nucleic acid molecule
An isolated nucleic acid molecule encoding a polypeptide comprising the amino acid sequence of SEQ ID NO:12.
An oligonucleotide less than 100 nucleotides in length comprising at least 9 contiguous nucleotides of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, or SEQ ID NO:11
A substantially purified polypeptide comprising amino acids 21-66 of SEQ ID NO:2 or SEQ ID NO:12.
16 A pharmaceutical composition comprising the polypeptide of claim 12 and a pharmaceutically acceptable carrier.
A kit comprising in one or more containers a compound selected from the group consisting of an CRF2-12 nucleic acid, an CRF2-12 polypeptide and an antibody to an CRF2-12 polypeptide.
A method of treating or preventing a pathological condition, the method comprising administering the antibody of claim 16 to a subject in an amount sufficient to alleviate or prevent the pathological condition.
A method of treating rheumatoid arthritis in a subject, the method comprising administering to the subject an agent that modulates the amount of a CRF2-12 polypeptide in said subject.
A method of treating multiple sclerosis in a subject, the method comprising administering to the subject an agent that modulates the amount of a CRF2-12 polypeptide in said subject.
A method of modulating vascular smooth muscle cell proliferation, the method comprising contacting a vascular smooth muscle cell with an agent that modulates the amount of CRF2-12 polypeptide in said cell.
A method of treating or preventing inflammation in a subject, the method comprising administering to said subject an agent that modulates the amount of a CRF2-12 polypeptide in said subject.
Dependencies are inferred from the claim text.